tiprankstipranks
Trending News
More News >
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
US Market

Acrivon Therapeutics, Inc. (ACRV) AI Stock Analysis

Compare
217 Followers

Top Page

AC

Acrivon Therapeutics, Inc.

(NASDAQ:ACRV)

Rating:36Underperform
Price Target:
Acrivon Therapeutics, Inc. faces major financial challenges, including no revenue, increasing losses, and negative cash flows, leading to a low overall score. The weak technical indicators further compound these concerns. However, recent corporate events, such as advancements in clinical programs and an extended cash runway, offer some optimism for future prospects. Investors should be cautious due to the company's current financial instability.
Positive Factors
Clinical Progress
Acrivon continues to progress its registrational intent P2b study of ACR-368 after refining its focus towards the endometrial cohort, where the strongest results were observed in the interim data.
Pipeline Development
Acrivon is continuing to build its pipeline, with a novel first-in-class cell cycle drug expected to be nominated for development within 2025.
Negative Factors
Efficacy Concerns
The ACR-368 platform's predictive power is weaker than anticipated, which diminishes its clinical value.
Market Pressure
The stock has experienced pressure following the company's R&D day due to the lower than expected efficacy of ACR-368 in endometrial cancer compared to previous updates and competitor drugs.

Acrivon Therapeutics, Inc. (ACRV) vs. SPDR S&P 500 ETF (SPY)

Acrivon Therapeutics, Inc. Business Overview & Revenue Model

Company DescriptionAcrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
How the Company Makes MoneyAcrivon Therapeutics, Inc. makes money primarily through the development and commercialization of its targeted oncology therapies. The company generates revenue by advancing its drug candidates through clinical trials with the aim of obtaining regulatory approval and subsequently marketing these therapies. Key revenue streams include potential licensing agreements, partnerships with other pharmaceutical companies, and milestone payments upon achieving specific clinical and regulatory milestones. Additionally, Acrivon may engage in collaborative research and development agreements to enhance its pipeline and broaden its market reach.

Acrivon Therapeutics, Inc. Financial Statement Overview

Summary
Acrivon Therapeutics, Inc. faces significant financial challenges with no revenue generation and increasing net losses. While the balance sheet shows a strong equity position, the cash flow is concerning due to heavy reliance on external financing. Overall, the financial health of the company needs improvement to ensure long-term viability.
Income Statement
10
Very Negative
The company has not generated any revenue over the analyzed period, which is a significant concern. Net income has consistently been negative, and losses have widened over time, with EBIT and EBITDA showing a similar trend. The lack of revenue and increasing losses place the company in a challenging financial position.
Balance Sheet
45
Neutral
The company maintains a strong equity position relative to its liabilities, with a high equity ratio. However, the total debt has been managed at a low level, which is a positive sign. Despite these strengths, the consistent net losses reduce the overall value of the equity position.
Cash Flow
30
Negative
Operating cash flow has been consistently negative, indicating that the company is not generating enough cash to cover its operating expenses. Free cash flow is also negative, and the company relies heavily on financing activities to offset cash deficits. This reliance poses potential long-term sustainability risks.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit-200.00K0.00-536.00K-1.09M-832.00K-13.00K
EBITDA-92.64M-79.55M-59.85M-30.07M-15.41M-5.29M
Net Income-83.75M-80.56M-60.39M-29.68M-16.24M-5.31M
Balance Sheet
Total Assets176.35M196.59M138.26M181.23M106.59M2.19M
Cash, Cash Equivalents and Short-Term Investments149.63M179.48M127.46M127.75M99.60M1.58M
Total Debt3.51M3.65M4.64M4.96M5.63M58.00K
Total Liabilities15.96M19.80M17.07M10.75M130.40M10.60M
Stockholders Equity160.39M176.79M121.19M170.47M-23.81M-8.41M
Cash Flow
Free Cash Flow-70.13M-68.44M-43.93M-32.28M-14.22M-2.82M
Operating Cash Flow-68.12M-65.67M-42.64M-30.12M-13.98M-2.80M
Investing Cash Flow-38.41M-51.77M50.72M-141.68M-238.00K-15.00K
Financing Cash Flow120.86M121.03M-1.55M101.71M112.22M2.89M

Acrivon Therapeutics, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.23
Price Trends
50DMA
1.29
Positive
100DMA
2.70
Negative
200DMA
4.83
Negative
Market Momentum
MACD
-0.03
Negative
RSI
51.36
Neutral
STOCH
40.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRV, the sentiment is Positive. The current price of 1.23 is below the 20-day moving average (MA) of 1.25, below the 50-day MA of 1.29, and below the 200-day MA of 4.83, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 51.36 is Neutral, neither overbought nor oversold. The STOCH value of 40.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACRV.

Acrivon Therapeutics, Inc. Risk Analysis

Acrivon Therapeutics, Inc. disclosed 80 risk factors in its most recent earnings report. Acrivon Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Acrivon Therapeutics, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
51
Neutral
$48.67M-546.55%127.51%56.94%
47
Neutral
$52.41M678.24%-69.59%
45
Neutral
$80.32M-196.81%
38
Underperform
$57.43M-679.15%-56.88%-57.57%
38
Underperform
$7.99M-1949.77%-89.76%80.28%
36
Underperform
$38.57M-62.41%10.84%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ACRV
Acrivon Therapeutics, Inc.
1.29
-4.85
-78.99%
CYCC
Cyclacel Pharmaceuticals
0.25
-25.83
-99.04%
BLUE
Bluebird Bio
4.97
-13.32
-72.83%
AVTX
Avalo Therapeutics
4.94
-6.70
-57.56%
STRO
Sutro Biopharma
0.76
-2.12
-73.61%
GUTS
Fractyl Health, Inc.
1.64
-2.83
-63.31%

Acrivon Therapeutics, Inc. Corporate Events

Executive/Board Changes
Acrivon Therapeutics Appoints New Chief Medical Officer
Positive
Apr 7, 2025

On April 7, 2025, Acrivon Therapeutics announced the appointment of Mansoor Raza Mirza, M.D., as Chief Medical Officer, effective April 9, 2025. Dr. Mirza, a distinguished oncologist with a robust background in gynecologic oncology, will lead clinical development efforts, including the ongoing ACR-368 Phase 2b trial in endometrial cancer and the ACR-2316 Phase 1 study. His appointment is expected to strengthen Acrivon’s clinical leadership and advance the company’s pipeline towards regulatory submissions and potential approvals, enhancing its position in the precision oncology field.

Spark’s Take on ACRV Stock

According to Spark, TipRanks’ AI Analyst, ACRV is a Underperform.

Acrivon’s overall stock score is low due to significant financial challenges, including no revenue, increasing losses, and negative cash flows. The weak technical indicators further compound these concerns. However, recent corporate events showing progress in clinical programs and an extended cash runway offer some optimism for future prospects.

To see Spark’s full report on ACRV stock, click here.

Business Operations and StrategyFinancial Disclosures
Acrivon Therapeutics Reports 2024 Financial Results and Progress
Positive
Mar 27, 2025

On March 27, 2025, Acrivon Therapeutics announced its financial results for the fourth quarter and full year 2024, highlighting significant progress in its clinical programs. The company reported promising data from its ACR-368 trials for endometrial cancer, showing a high response rate in heavily pretreated patients, and prioritized this cancer type due to limited treatment options and commercial potential. Additionally, the Phase 1 trial of ACR-2316 is ahead of schedule, with early signs of clinical activity. Acrivon has extended its cash runway into 2027, allowing continued focus on its AP3 platform and drug development efforts.

Executive/Board Changes
Acrivon Therapeutics Appoints New Chief Financial Officer
Neutral
Mar 14, 2025

On March 14, 2025, Acrivon Therapeutics announced the appointment of Adam Levy, Ph.D., M.B.A., as Chief Financial Officer effective April 1, 2025. Dr. Levy brings over 25 years of experience in finance and investor relations within the biopharma sector, having previously held senior roles at companies like Zentalis Pharmaceuticals and Gilead Sciences. His appointment follows the departure of Rasmus Holm-Jorgensen, who is stepping down for personal reasons to pursue an opportunity in Europe. This leadership change is not due to any disagreements within the company, and it is expected to strengthen Acrivon’s financial strategy and investor relations.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 26, 2025